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COVID-19has resulted in thedeferral ofmajor surgery for genitourinary (GU) cancers
with the exceptionof cancerswith a high risk of progression.We report outcomes for
major GU cancer operations, namely radical prostatectomy (RP), radical cystectomy
(RC), radical nephrectomy (RN), partial nephrectomy (PN), and nephroureterectomy
performed at 13major GU cancer centres across the UKbetweenMarch 1 andMay 5,
2020. A total of 598 such operationswere performed. Four patients (0.7%) developed
COVID-19 postoperatively. There was no COVID-19–related mortality at 30 d. A
minimally invasive approach was used in 499 cases (83.4%). A total of 228 cases
(38.1%) were described as training procedures. Training case status was not associ-
ated with a higher American Society of Anesthesiologists (ASA) score (p = 0.194) or
hospital length of stay (LOS; p> 0.05 for all operation types). The risk of contracting
COVID-19 was not associated with longer hospital LOS (p = 0.146), training case
status (p = 0.588), higher ASA score (p = 0.295), or type of hospital site (p = 0.303).
Our results suggest that major surgery for urological cancers remains safe and
training should be encouraged during the ongoing COVID-19 pandemic provided
appropriate countermeasures are taken. These real-lifedata are important forpolicy-
makers and clinicians when counselling patients during the current pandemic.
Patient summary: We collected outcome data for major operations for prostate,
bladder, and kidney cancers during the COVID-19 pandemic. These surgeries remain
safe and training should be encouraged during the ongoing pandemic provided
appropriate countermeasures are taken. Our real-life results are important for poli-
cy-makers and clinicians when counselling patients during the COVID-19 pandemic.
© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).http://dx.doi.org/10.1016/j.euros.2021.01.005
2666-1683/© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1 – Patient characteristics stratified by type of surgery
All patients (n = 598) RP (n = 282) RC (n = 104) RN (n = 124) PN (n = 52) RNU (n = 36)
Median age, yr (IQR) 65.1 (58.5–71.3) 64.1 (59.0–68.6) 70.4 (60.4–75.4) 65.9 (58.5–73.4) 59.4 (52.1–68.5) 61.8 (62.5–75.4)
ASA score, n (%)
I 83 (13.9) 47 (16.7) 11 (10.5) 13 (10.5) 8 (15.3) 4 (11.2)
II 393 (65.7) 212 (75.1) 58 (55.8) 74 (59.7) 33 (63.5) 16 (44.4)
III 122 (20.4) 23 (8.2) 35 (33.7) 37 (29.8) 11 (21.2) 16 (44.4)
Surgical technique, n (%)
Open 99 (16.6) 1 (0.4) 39 (39.4) 46 (37.1) 7 (13.5) 6 (16.7)
Robotic 418 (69.9) 280 (99.3) 65 (62.5) 12 (9.7) 43 (82.7) 18 (50.0)
Laparoscopic 81 (13.5) 1 (0.4) 0 (0) 66 (53.2) 2 (3.8) 12 (33.3)
Training case, n (%)
No 370 (61.9) 173 (61.3) 69 (66.3) 68 (54.8) 34 (65.4) 26 (72.2)
Yes 228 (38.1) 109 (38.7) 35 (33.7) 56 (45.2) 18 (34.6) 10 (27.8)
Mean EOT SD (min)
Training cases 174.0 63.5 334.379.1 162.744.4 207.0 70.0 197.1 (56.2)
Non–training cases 159.6 59.5 255.7 80.3 145.160.4 181.9 63.9 209.5 (47.1)
Median LOS, d (IQR) 3.0 (1.0–5.0) 1.0 (1.0–2.0) 7.5 (6.0–11.8) 4.0 (3.0–6.0) 3.0 (2.0–4.0) 4.0 (3.0–5.0)
Developed COVID-19, n (%) 4 (0.7) 0 (0) 3 (2.9) 1 (0.8) 0 (0) 0 (0)
EOT = estimated operating time; IQRg = interquartile range; LOS = length of stay; PN = partial nephrectomy; RC = radical cystectomy; RN = radical nephrectomy;
RNU = radical nephroureterectomy; RP = radical prostatectomy; SD = standard deviation.
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resulted in deferment of between 29% and 53% of
genitourinary cancer surgeries globally [1]. Initial reports
suggest that 30-d mortality among patients who contracted
COVID-19 in the perioperative period was 23.8% [2]. Despite
the catastrophic effects of COVID-19, it remains necessary to
provide prompt cancer surgery with curative intent for
selected patients.
International societies and national bodies have pro-
duced guidelines aimed at minimising the risk of contract-
ing COVID-19 while balancing treatment options, although
these recommendations have been based on limited
evidence (Supplementary Table 1). The British Association
of Urological Surgeons (BAUS) recommended deferring
surgery for T1 kidney cancer and intermediate- and high-
risk prostate cancer, and referring patients with muscle-
invasive bladder cancer (MIBC) for radical radiotherapy over
radical cystectomy (RC) [3]. Initial guidance from the Royal
College of Surgeons (RCS) suggested that laparoscopy
should not be used owing to the risk of aerosol formation
[4]. The European Association of Urology (EAU) recom-
mends that minimally invasive procedures should be
performed by experienced surgeons, which would limit
training opportunities [5]. As further peaks of COVID-19
infection are anticipated, we sought to explore the impact of
recommendations in the context of surgery for major
genitourinary (GU) malignancy to provide an evidence base
for policy makers.
In this retrospective study, we report outcomes formajor
GU cancer operations, namely radical prostatectomy (RP),
RC, radical nephrectomy (RN), partial nephrectomy (PN),
and nephroureterectomy, performed at 13 UK major cancer
referral centres between March 1 and May 6, 2020. Early in
the study, all hospitals adopted standard perioperative
assessments and precautions. The reduction in operations
carried out was due to the deferment of cases deemed “less
urgent” in view of the competing risk of contracting COVID-19 as well as the requirement for nursing and medical staff
to work in expanded intensive care units across the UK.
For patients undergoing surgery at hot sites, operations
were performed in theatres purely reserved for elective
non–COVID-19 patients, which in most cases, are in a
separate area of the hospital away from patients admitted
with COVID-19 infections. Postoperatively, patients were
allocated to COVID-19–free wards (green zone) and swabs
were taken for SARS-CoV-2 detection if there was a clinical
suspicion of COVID-19. Additional COVID-19 safety precau-
tions are described in the Supplementary material. Adher-
ence to guidelines was variable between hospitals and the
decision to perform surgerywas based on risk assessment at
a local level. Institutional reviewboards exempted thiswork
from ethical approval as it represents an audit of clinical
practice.
Patient and hospital characteristics recorded include age,
American Society of Anesthesiologists (ASA) score (1, 2,3),
surgical approach (open, robotic, laparoscopic), hospital
length of stay (LOS), and whether an operation was a
training case, defined as a urology resident performing part
or all of the operation. COVID-19 infection was defined as
patients with a positive polymerase chain reaction swab or
clinical features consistent with COVID-19 infection. The
primary endpoint was 30-d all-cause mortality and COVID-
19–related death.
We included 598 patients in the current analysis (Table 1,
Supplementary Table 2). Figure 1 illustrates the weekly
cumulative tally of operations performed across all sites.
There was a notable decline in the number of operations
when the UK-wide confirmed COVID-19 deaths peaked. Four
patients (0.7%) developed COVID-19 postoperatively (n = 3 at
hot sites; n = 1 at a cold site), of whom threewere discharged
from hospital and one remains an inpatient because of
postoperative complications. There was no COVID-19–relat-
edmortalityat30d.Twopatients (0.3%;RCandPN)died from
sepsis and multiorgan failure postoperatively which were
[(Fig._1)TD$FIG]
Fig. 1 – Number of weekly and cumulative UK COVID-19–related deaths and number of surgical operations performed on a weekly basis across all
13 hospitals. NU = nephroureterectomy; PN = partial nephrectomy; RC = radical cystectomy; RN = radical nephrectomy; RP = radical prostatectomy.
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who cared for the four patients who tested positive for
COVID-19 developed the infection.
A minimally invasive approach was used in 499 cases
(83.4%). A total of 228 cases (38.1%) were described as
training procedures (Table 1). There was no significant
association between training case status and higher ASA
score (p = 0.194) or hospital LOS (p> 0.05 for all operation
types). The patient risk of contracting COVID-19 was not
associated with longer hospital LOS (p = 0.146), trainingcase status (p = 0.588), higher ASA score (p = 0.295), and
type of hospital site (p = 0.931). The median operating time
was longer for training cases than for non–training cases;
however, with the exception of radical cystectomy (p<
0.001), there were no significant differences in mean
operating time between the two groups (Table 1).
Our findings suggest thatmajor GU cancer surgery can be
safely performed if appropriate countermeasures are taken.
We report no 30-d COVID-19–related mortality, with a
minimal risk of contracting COVID-19 of 0.7%. While we
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contract COVID-19 perioperatively have a high risk of
mortality, our data suggest that the risk of COVID-19
infection isminimal with safety precautions [2]. In addition,
training should be encouraged, as this had no impact on the
risk of COVID-19 transmission and hospital LOS.
It is established that a delay in radical treatment for
localised cancer carries the risk of disease progression to the
point at which such treatment may no longer be curative
[6,7]. Early in the pandemic, there was an emphasis on
minimising the competing risk of death due to COVID-19
infection. Patients with cancer are often older, making them
more susceptible to COVID-19. In the case of RC in particular,
concerns about prolonged operating times, potential
admission to the intensive care unit, and prolonged hospital
stay increasing the risk of COVID-19 transmission appear to
be unproven provided adequate precautions are taken
(Supplementary material) [8].
Critics of surgery during the COVID-19 pandemic often
cite alternatives such as radiation therapy. Radiotherapy
with or without hormones is a valid alternative in the case
of prostate cancer. However, there is a scarcity of data
regarding the competing risk of COVID-19 transmission
during attendance at a radiotherapy facility up to 37 times
for treatment when compared to an overnight hospital
admission. Furthermore, it has been reported that the
requirement for androgen deprivation therapy increases
cardiovascular risk [9]. In the case of RC, while selected
MIBC patients experience a good outcome from bladder-
sparing approaches, oncological equivalence cannot be
guaranteed [10]. Our results suggest that a significant
number of UK centres did not adhere to recommendations
and continued to offer RC, probably because of oncological
concerns regarding radiotherapy. For T2 kidney cancer,
surgery remains the only viable option. Equally important is
patient choice, and patients often have a preference for one
treatment over another. We believe that after proper
counselling, referral for surgery should be an option for
patients.
There is no doubt that COVID-19 has significantly
impacted training. Our results suggest that cases performed
by trainees under supervision have no bearing on the risk of
COVID-19 transmission. Hence, our data support the
continuance of training, particularly because COVID-19
transmission is likely to persist.
We acknowledge limitations of the study. The cohort
described represents a well-selected patient group who
were deemed suitable for surgery by their urologist
following multidisciplinary team review during the
COVID-19 pandemic. We have attempted to generalise
our results to UK hospitals by performing a multicentre
study, but acknowledge that our experience may not be
generalisable to other countries. Finally, there remained
variability over timing of the peak incidence of COVID-19
deaths across the country, although the peak for COVID-19
deaths experienced by each contributing hospital was
captured during the study period.
Our results suggest that major surgery for urological
cancers remains safe and that training should be encouragedduring the ongoing COVID-19 pandemic provided appropri-
ate countermeasures are taken. These real-life data are
important forpolicy-makers andclinicianswhen counselling
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